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ABSTRACT  
Background: Hepatic stellate cells (HSC) are vital to hepatocellular function and the 
liver response to injury. They share a phenotypic homology with astrocytes that are 
central in the pathogenesis of hepatic encephalopathy, a condition in which 
hyperammonemia plays a pathogenic role. This study tested the hypothesis that 
ammonia modulates human HSC activation in vitro and in vivo, and evaluated 
whether ammonia lowering, by using L-ornithine phenylacetate (OP), modifies HSC 
activation in vivo and reduces portal pressure in a bile duct ligation (BDL) model.  
Methods: Primary human HSCs were isolated and cultured. Proliferation (BrdU), 
metabolic activity (MTS), morphology (TEM, light-and immunofluorescence 
microscopy), HSC activation markers, ability to contract, and changes in oxidative 
status (ROS) and endoplasmic reticulum (ER) were evaluated to identify effects of 
ammonia challenge (50 µM, 100 µM, 300 µM) over 24-72hrs. Changes in plasma 
ammonia levels, markers of HSC activation, portal pressure and hepatic eNOS 
activity were quantified in hyperammonemic BDL animals, and after OP treatment. 
Results: Pathophysiological ammonia concentrations caused significant and 
reversible changes in cell proliferation, metabolic activity and activation markers of 
hHSC in vitro. Ammonia also induced significant alterations in cellular morphology, 
characterised by cytoplasmic vacuolisation, ER enlargement, ROS production, hHSC 
contraction and changes in pro-inflammatory gene expression together with HSC-
related activation markers such as α-SMA, myosin IIa, IIb, and PDGF-Rβ. Treatment 
with OP significantly reduced plasma ammonia (BDL 199.1µmol/L±43.65 vs. 
BDL+OP 149.27µmol/L±51.1, P<.05) and portal pressure (BDL 14±0.6 vs. BDL+OP 
11±0.3 mmHg, P<.01), which was associated with increased eNOS activity and 
abrogation of HSC activation markers. 
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Conclusions: The results show, for the first time, that ammonia produces 
deleterious morphological and functional effects on HSCs in vitro. Targeting 
ammonia with the ammonia-lowering drug OP reduces portal pressure and 
deactivates hHSC in vivo, highlighting the opportunity for evaluating ammonia 
lowering as a potential therapy in cirrhotic patients with portal hypertension. 
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Introduction 
Hepatic stellate cells (HSC) orchestrate many important functions in the liver and 
their activation and consequent dysfunction is associated with many complications 
including hepatic fibrosis, portal hypertension and liver cancer.[1-3] Astrocytes are 
cells that are centrally involved in the pathogenesis of hepatic encephalopathy (HE), 
an important complication of cirrhosis.[4, 5] Hyperammonemia is a feature of liver 
failure and over the past 120 years many studies have demonstrated incontrovertibly 
its central role in the pathogenesis of HE.[6, 7] The mechanism of ammonia-induced 
HE is hypothesised to be through induction of astrocytic osmotic stress swelling 
induced by glutamine derived from ammonia detoxification by the action of glutamine 
synthase.[4, 5] More recently, it has been shown that ammonia itself and/or the 
resulting of cell swelling can initiate a cascade of pathological events such as 
oxidative stress, resulting in RNA oxidation-and nitrosative stress, leading to nitration 
of critical proteins.[8] Many studies have indicated that human HSC, like astrocytes 
share similar markers when activated indicating that they belong to a similar 
mesodermal origin.[9-12] Both cell types are characterised by a large cytokine 
repertoire including NFkB-induced pro-inflammatory cytokines.[13-16]  
Previous work showed that rat HSCs express glutamine synthetase leading to our 
hypothesis that excess ammonia may therefore produce deleterious effects on the 
activity and function of primary human HSC as it does in astrocytes.[17] Following 
acute or chronic liver injury, HSCs undergo phenotypic transformation from 
“quiescent” (non-proliferating and non-contractile) to “activated” (promitogenic, 
profibrogenic, and proinflammatory myofibroblasts-like) cells. Moreover, during the 
process of activation, HSCs become highly contractile and develop the necessary 
machinery to contract or relax in response to a number of vasoactive 
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substances/stimuli.[18-25] Several lines of investigation indicate that activation of 
HSCs and their ability to contract represent crucial contributory mechanisms 
associated with the development of portal hypertension, [21, 22, 26] the severity of 
which has been shown to result in variceal bleeding and a hepatic venous pressure 
gradient of greater than 10 mmHg is strongly predictive of future 
decompensation.[27]  
 
The aim of the present study, was to test the hypothesis that ammonia further 
activates human HSCs (hHSC) in vitro and has consequences on hHSC biology. We 
then tested whether this activation of hHSC occurred in vivo by induction of 
hyperammonemia in a bile duct ligated animal model (BDL). Finally, we tested 
whether reduction of ammonia by administration of an ammonia-lowering drug L-
ornithine phenylacetate (OP) (OCR-002) [28, 29] in BDL rats was associated with a 
negative modulation of HSC activation and in the reduction of portal pressure. 
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Materials & Methods 
Please refer to the Supplementary Materials and Methods, and Information section 
for more detailed descriptions.  
 
In vitro studies in human HSC 
Primary Human HSCs (hHSC) were isolated from wedge surgical sections of liver 
normal liver tissue, obtained from patients undergoing surgery in the Royal Free 
Hospital after giving informed consent (EC01.14-RF). Cells were isolated according 
to Mederacke et al., [30] with the relative modifications for human liver.[31] Briefly, 
10 g of total human liver tissue was digested with 0.01% Collagenase, 0.05% 
Pronase and 0.001% DNase I without performing perfusion. The homogenate was 
filtered through a 100µm cell strainer and the flow-through was centrifuged at 50xg 
for 2 minutes at 4°C. After washing the supernatant, gradient centrifugation was 
performed at 1400xg for 17 minutes at 4°C using an 11.5% Optiprep gradient. 
Finally, the interface was collected and washed. Purity of hHSC was established by 
detection of CD140b (PDGFRbeta), CD29 (Integrin beta 1) and Cytoglobin (CYGB). 
The obtained HSCs were cultured in RPMI supplemented with 20% foetal bovine 
serum (FBS), GLUTAMAX, nonessential amino acids 1X, 1.0 mM sodium pyruvate, 
1X antibiotic-antimycotic (all Life Technologies), referred to as complete HSC 
medium hereinafter. Experiments described in this study were performed on hHSC 
of at least three independent cell preparations between passage 3 and 8.  
Treatment: Cells were seeded (density 26x103/cm2) under basic serum-rich 
conditions (CM complete medium) for 24 hours, followed by serum deprivation for 
another 24 hours (SFM). It is well established that ammonia leads to the production 
of glutamine when GS is present and conversely, glutamine can lead to the 
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generation of ammonia, not allowing the effects of exogenous ammonia to be 
studied. Thus, exogenous glutamine was removed from the culture medium to avoid 
a confounding element in the experimental protocol. Specific treatment with NH4Cl 
treatments were replaced daily for the duration of the experiment as described in 
Supplementary information.  
 
Animal Models  
Animals. All animal experiments were conducted according to the Home Office 
guidelines under the UK Animals in Scientific Procedures Act 1986 with approval of 
the ethical committee for animal care of University College London. This study was 
performed in male Sprague-Dawley rats (Charles River UK, Margate, UK), weighing 
220–250 g.  
In one experimental model, rats were administered a high protein/ammoniagenic diet 
(AAs) for 5 days.[13, 32] Furthermore, all rats underwent BDL to induce cirrhosis or a 
sham operation as described previously.[33] 
Study design. (i) In this experimental protocol, animals underwent BDL surgery and 
were given 4 weeks to develop liver injury. During the 4th week, BDL animals were 
randomized into 3 groups: one group included BDL rats receiving an amino acid-rich 
(AAs) diet in addition to injection of intraperitoneal (i.p.) saline solution (n=4); a 
second group received the AAs diet and was treated with an i.p. injection of the 
ammonia-lowering agent OP 0.3 g/kg twice a day for 5 days (n=4); the third group 
consisted of BDL rats receiving saline solution i.p. (n=4). In addition to the BDL 
animals, a further group of sham-operated rats received saline solution (i.p.) (n=4). 
Animals were sacrificed on the 5th day of treatment.  
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(ii) In a second experimental protocol, the effect of the ammonia-lowering agent OP 
on ammonia-induced portal hypertension was investigated. Four weeks after BDL or 
sham operation, rats were randomized into three groups: sham-operated rats 
receiving saline (i.p.) (n=18) twice a day for the experimental period of 5 days; BDL 
rats (n=20) were administered i.p. saline twice a day for 5 days; a further group of 
BDL rats (n=11) received i.p. injection of OP 0.3 g/kg twice a day for 5 days. 
Between weeks 4 and 5, following anesthesia (2% isofluorane), rats from each group 
underwent assessment of mean arterial pressure via isolation and cannulation of the 
right carotid artery. In addition, portal pressure was measured by direct cannulation 
of the main portal vein. All measurements were transduced to a Powerlab (4SP) 
linked to Chart v5.0.1 software. The mean of three readings taken one minute apart 
was recorded. Liver tissue was harvested and snap-frozen for storage at 80°C until 
analyzed.   
 
Statistical analysis 
Results are expressed as mean values ± SEM and compared using one-way 
analysis of variance followed by Dunnet's or Tukey's multiple comparison post hoc 
tests, where appropriate. P values ≤0.05 were considered significant.  
In vivo experimental data were analysed by t tests and Mann-Whitney U test as 
appropriate; P <0.05 was considered statistically significant. Results are presented 
as mean values ± SEM using GraphPad Prism software (GraphPad, La Jolla, CA).  
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Results 
Ammonia reduces cell proliferation and metabolism in human Hepatic Stellate 
Cells in vitro in a dose dependent manner 
Human HSC treated with different concentrations of ammonia for 72 hours showed a 
significant inhibition in cell proliferation (BrdU assay) and metabolic activity (MTS 
assay) (Fig. 1A). Furthermore, long term treatment of hHSC with ammonia did not 
cause cell death as assessed by deploying the Cell Death Detection ELISA (Fig. 
1B). Also, these ammonia-induced effects coincided with strong alterations in cellular 
morphology in a dose-dependent manner as observed by light microscopy (Fig. 1C). 
Treatment with ammonia led to drastic changes in cell morphology with the 
appearance of a spindle-like fibroblast phenotype, and signs of deregulation of the 
endo-lysosomal compartment as assessed by Neutral Red, a dye retained by the 
lysosomes (Fig. 1C). As demonstrated in Supplementary Fig.1 human HSC express 
GS at the mRNA and protein level. Pretreatment of cells with MSO, a biochemical 
inhibitor of GS, followed by exposure to ammonia did not further inhibit proliferation 
and metabolic activity in comparison to MSO treatment only (Supplementary Fig. 
1). 
 
Ammonia induces alterations in cytoplasmic stress, which coincides with 
changes in cellular metabolism/function and actin cytoskeleton architecture 
The morphological changes observed by light microscopy were further characterised 
by performing ultrastructural studies. Ammonia caused a dramatic dose-dependent 
change in the cytosol with ER enlargement and marked presence of translucent 
vacuoles. Neither mitochondrial alterations nor presence of autophagic structures 
(characterised by double membranes) were observed (Fig. 2A). Of importance is the 
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fact that when ammonia-rich medium was removed and cells were replenished with 
complete medium both cell proliferation and metabolic activity were restored (Fig. 
2B), thus supporting the idea that the observed effect of ammonia is transient. 
Moreover, ammonia-treated hHSC cultured on collagen gels showed a significant 
ability to contract (Fig. 2C, 2D) when compared to control. This effect was observed 
as soon as three hours of ammonia treatment and appeared to be still sustained 
after 24 hours which coincided with the previously observed morphological changes 
(Fig. 2E). Furthermore, long-term treatment with ammonia (72 hours) induced a 
dose-dependent re-organization of filamentous actin in the cytoskeleton when 
TRICT-Phalloidin staining was employed. Re-organization of the F-actin network 
coincided with the presence of translucent vacuoles in a dose depended manner 
(Fig. 2F).  
 
Ammonia induces ER enlargement 
As the ultrastructural study showed a marked ammonia-dependent dysregulation 
and enlargement of the ER compartment, we then further evaluated the status of ER 
stress. To this end, cells were cultured and treated with ammonia as previously 
described, for 1, 3 up to 24 hours, followed by qPCR for two ER stress marker genes 
i.e. ATF6 and XBP1. Both, mRNA expression levels were up-regulated in a dose-and 
time dependent manner with a marked up-regulation after 3 hours for all ammonia 
concentrations tested, which decreased again after 24 hours of treatment (Fig. 3A). 
Moreover, pre-treatment with TUDCA, a bile salt derivate with ER-chaperone 
properties, alleviated the previously shown increase in ammonia-induced ATF6 and 
XBP1 mRNA expression after 3 hours. Prolonged treatment with ammonia for 72 
hours, altered the ER dynamics with a strong peri-nuclear accumulation of ER-
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Tracker™ Red dye and the presence of cytoplasmic vacuoles with increasing 
ammonia concentrations (Fig. 3C).  
 
Hyperammonemia induces ROS production in hHSC 
As ER stress is associated with or/and leads to ROS formation, the possibility that 
ammonia stimulates ROS production was assessed. Prolonged treatment of cells 
with ammonia for up to 72 hours showed a gradual development of ROS as detected 
by the presence of cytosolic carboxy-DCF (Fig. 4A). The development of ammonia-
induced ROS production was further quantitatively measured as described 
previously,[34] and confirmed that primary hHSCs treated with ammonia produced 
significant ROS (Fig. 4B). Next, cells treated with ammonia for different time points 
showed a strong increase in mRNA expression of Superoxide dismutase 2 (SOD2) 
after 3 hours, which was sustained at 24 hours of ammonia treatment (Fig. 4C). 
Moreover, pre-treatment with N-acetyl cysteine (NAC), a known ROS scavenger, 
showed no impact on the previously observed increase in SOD2 mRNA expression 
after 3 hours of ammonia treatment. In contrast, pre-treatment with NAC followed by 
ammonia treatment for 24 hours, almost completely abolished ammonia-induced 
SOD2 mRNA expression.  
 
Ammonia alters the pro-fibrogenic/pro-inflammatory profile in hHSC 
Next, the possibility that ammonia-induced ROS formation causes alterations in 
HSC-related activation markers and pro-inflammatory genes was investigated. As 
shown in Fig. 5A, ammonia was shown to significantly increase α-SMA protein 
expression. At 300µM ammonia, vimentin (an important intermediate filament) 
synthesis was increased. Both Myosin IIa (that plays a key role in HSC contraction) 
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and Myosin IIb (implicated in HSC activation), were significantly modulated by 
increasing concentrations of ammonia. A dose-dependent response to ammonia was 
also observed in P-38 MAPK expression. Furthermore, PDGFR-β, important in HSC 
cell proliferation, showed a significant up-regulation under influence of ammonia, 
whereas Collagen type I showed a tendency to increase by ammonia, albeit these 
effects were not statistically significant (Fig. 5A). Furthermore, ammonia induced a 
strong and significant up-regulation of MMP2 mRNA expression, whereas mRNA 
expression of TIMP1 was down-regulated (Fig. 5B). Moreover, pro-inflammatory 
Interleukin-1β mRNA expression was significantly induced when hHSC were treated 
with ammonia 300 µM for 72 hours (Fig. 5C), whereas ammonia at 50 µM and 100 
µM doses significantly up-regulated Interleukin 6 mRNA expression level. By 
contrast, ammonia did not modify Interleukin 8 mRNA expression in HSC (Fig. 5C).  
 
In vivo study I: Bile duct ligation and ammonia treatment modifies HSC cell 
biology in vivo 
In a first set of in vivo experiments the effect of hyperammonemia on HSC-related 
signalling pathways in whole liver tissue was investigated. As previously 
described[13] ammonia concentrations were noted to be significantly elevated in 
BDL rat plasma compared to sham-operated rats (149.3µmol/L±51.1 vs. 
107.4µmol/L±23.2, P < .05). Plasma ammonia levels further increased when animals 
were fed an amino acid-rich (AAs) diet in combination with BDL surgery 
(199.1µmol/L±43.6 vs. 149.3µmol/L±51.1, P < .05) (Fig. 6A). More importantly, 
plasma ammonia levels decreased significantly when BDL-AAs-fed animals were 
treated with OP (123.9µmol/L±16.1 vs.199.1µmol/L µM±43.6, P < .001) (Fig. 6A). 
These significant changes in ammonia plasma levels were correlated with alterations 
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in portal pressure which was significantly higher in BDL rats and BDL-AAs-fed 
animals compared to sham (Supplementary Fig. 2). Expectedly, as the animals in 
the OP group were only treated for 5-days, no differences in collagen accumulation, 
assessed by Picrosirius Red staining, was demonstrated between BDL–AAs-fed 
animals and BDL–AAs-fed OP treated animals (Supplementary Fig. 3).  
Of note, the observed changes in haemodynamics post OP treatment coincided with 
a marked decrease in protein expression of HSC-related activation markers (Fig. 
6B). More specifically, BDL in combination with hyperammonaemia (AAs diet) 
showed a significant increase in Myosin IIb, Collagen type I, and PDGF-Rβ protein 
expression in comparison to BDL. In contrast, treatment with OP abrogated the 
strong effect of hyperammonaemia on BDL rat livers in relation to all HSC-related 
activation markers tested (Fig. 6B). 
 As ammonia-induced ER enlargement in hHSCs in vitro (Fig. 3A) the expression of 
ER stress-markers (CHOP and BiP) was evaluated in vivo. CHOP protein expression 
was increased in BDL and BDL-AAs-fed animals in comparison to sham-operated 
animals, with a minor but significant down regulation in BDL–AAs-fed and OP-
treated animals (Fig. 6C). In contrast, BiP protein expression was significantly down 
regulated in all BDL treated animals in comparison to Sham-operated rats, whereas 
OP treatment significantly prevented BiP protein down regulation in comparison to 
BDL–AAs-fed animals (Fig. 6C). Overall, these data indicate that OP treatment 
abolishes ammonia-induced ER-stress, with associated reduced HSC activation and 
consequent reduction in portal pressure.  
 
In vivo study II: Treatment with OP improves portal pressure through reduction 
in nitrosative stress 
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As described above, in the second in vivo study, ammonia concentrations were 
noted to be significantly elevated in BDL rat plasma compared to sham-operated rats 
(182±12.8 vs. 62.51±6.2 µM, P < .0001), and this decreased significantly following 
treatment with OP (83.8±16.3 µM, P < .0001). These significant changes in plasma 
ammonia were correlated with alterations in portal pressure, which was significantly 
higher in BDL rats compared to sham (14±0.6 vs.5.5±0.3 mmHg, P < .0001) (Fig. 
7A). Ammonia lowering through administration of OP resulted in a significant 
reduction in portal pressure compared to BDL –saline treated rats (11±0.3 mmHg, P 
< .01). Mean arterial pressure (MAP) was significantly higher in sham rats compared 
with BDL animals (105±2.3 vs 80±2.9 mmHg, P < .001). Following OP therapy, there 
was no significant change in MAP observed between BDL saline and OP treated rats 
(Fig. 7A). As a consequence of the ammonia-induced inflammatory and oxidative 
pathways observed in HSCs in vitro, and the effect of hyperammonemia on HSC-
related activation markers in vivo, the impacts on nitrosative stress was also 
assessed in whole liver tissue. When compared to sham-operated rats, there were 
significant increases in iNOS protein expression in BDL rats (Fig. 7B). Treatment 
with OP significantly reduced iNOS expression when compared to BDL control 
animals. Moreover, 3-NTyrosine expression (as an indication of increased nitrosative 
stress), was also significantly up-regulated in BDL treated animals compared to 
sham animals and this was reduced significantly following treatment with OP (Fig. 
7C). eNOS protein expression was significantly increased in BDL rats compared to 
sham animals (as we previously described[34]) and this remained statistically 
unchanged after OP therapy (Fig. 7C). More importantly, a significant reduced eNOS 
enzyme activity was observed in BDL rat liver compared to sham-operated animals, 
which was restored to near normal levels after OP therapy. Furthermore, the 
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expression of Caveolin-1 (an intracellular eNOS inhibitor) was found to be 
significantly higher in BDL livers compared to sham rats. In contrast, in BDL animals 
treated with OP, Caveolin-1 expression showed a significant down regulation in 
comparison to BDL rats (Fig. 7C). 
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Discussion 
The results of this study reveal, for the first time, that pathophysiologically relevant 
concentrations of ammonia produce marked deleterious consequences on HSCs in 
vitro and in vivo including: changes in endoplasmic reticulum dynamics and increase 
cellular oxidative stress, which are transient and can be prevented by intervention, 
providing therapeutic opportunities. Reduction in ammonia concentration using the 
ammonia-lowering drug OP, for a short term treatment of 5 days, resulted in a down 
regulation of HSCs activation markers in BDL rats that coincided with a significant 
reduction in portal pressure, providing a potential novel strategy to treat portal 
hypertension. 
The first set of experiments clearly showed that increasing concentrations of 
ammonia were associated with marked structural and functional changes of hHSCs. 
This was not associated with any evidence of cell-death and notably these effects 
were reversible when ammonia was removed from the medium and cells were 
allowed to recover. Hence, providing the first indication that ammonia-induced 
dysfunction of HSCs is reversible. In accordance with prior observations in rat 
HSCs[17], human HSCs also express GS. Interestingly, although GS gene 
expression remained unaffected by increasing concentrations of ammonia, a 
significant reduction in protein levels was observed. The mechanism(s) of this 
reduction is not clear but may be a consequence of reduced detection or breakdown, 
as ammonia has been shown to nitrosylate GS in astrocytes.[35-37]  
These changes in functionality as observed in this study were closely associated 
with dose-dependent morphological alterations, as assessed by light and 
transmission electron microscopy. On light microscopy, cells appeared longer, 
spindly and also presented marked vacuolization. These alterations were further 
  
26 
 
confirmed by ultra-structural analysis as evidenced by dose-dependent cytoplasmic 
vacuolization, with no significant nuclear alterations. Whilst the treatment of 
astrocytes with ammonia has been shown to induce mitochondrial swelling [38] and 
autophagy, in this study, ammonia induced cytoplasmic vacuolization in hHSCs was 
without the formation of autophagic bodies or alterations in mitochondrial structure. 
Indeed, ammonia-induced autophagy has been shown to be cell type and context 
dependent.[39, 40] These morphological changes coincided with modifications in the 
actin cytoskeletal architecture such as the re-organization in filamentous actin and a 
significant up-regulation in α-SMA and myosin IIa protein expression, after a 
prolonged treatment with ammonia. Furthermore, ammonia induced contraction of 
hHSC, indicating that ammonia strongly affects actin, which is important in 
maintaining HSC cell integrity and function.  
In this study, evidence of marked ER swelling and vacuolisation was observed. The 
ER uses its protein folding status as a signal to orchestrate downstream apoptotic or 
adaptive responses and the ER is known as a key player in the process of liver 
damage.[41] Moreover, it is known that ER stress can induce activation of primary 
hHSC and induce its morphological changes and dysfunction through induction of 
autophagy.[42] In this study, ammonia induced, in a time dependent manner, ER 
stress markers, which coincided with up-regulation of HSC activation markers but 
without affecting apoptosis and autophagy. Moreover, the co-involvement of 
ammonia-induced ER stress in hHSC was further demonstrated by using 
Tauroursodeoxycholic Acid (TUDCA) [40] known to exert protection from liver injury 
by inhibiting ER-stress.  
In order to determine the effectors of these functional and morphological changes 
induced by ammonia, our study further focused on the development of oxidative 
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stress. It was remarkable to note that the hHSC were very sensitive to ammonia in 
inducing intracellular production of reactive oxygen species as assessed by a 
quantitative fluorometric assay. The mechanisms of this increase in ROS with 
ammonia are not entirely clear but are thought to be consequent upon ER 
enlargement and cell swelling and/or generation of cytokines as shown in this study. 
Indeed, the co-involvement of ammonia-induced ER-stress followed by ROS 
formation in hHSC was further demonstrated by using TUDCA and NAC, inhibitors of 
ER stress and scavenger of ROS respectively. Moreover, this increase in oxidative 
stress can have deleterious consequences on chronic activation of wound 
healing.[43] Similar results are well established for the role of ROS production in 
portal hypertension, that result in a paracrine activation and proliferation of hepatic 
sinusoidal endothelial cells, which in turn will activate HSCs resulting in their 
proliferation, migration, contraction and further fibrogenesis.[44-46] The cross talk 
between HSCs and LSEC needs further investigation, as this complex interaction, 
may be impacted upon by reduction in ammonia concentrations.  
Overall, the ammonia-induced ROS production affects the mRNA and protein 
expression levels of HSC activation markers and several pro-inflammatory 
interleukins. It was therefore notable that the protein expression for p38MAP kinase 
was increased by ammonia in the hHSC, which is a key signal transduction mediator 
of inflammation in many cell types.[47] Previous studies have indicated a similar up-
regulation of gene and protein expression of p38MAP kinase in astrocytes and also 
in neutrophils after exposure to ammonia. In fact, inhibition of p38MAP kinase in 
neutrophils reversed this ammonia-induced functional derangement.[32, 48, 49] 
In order to determine whether this observation in vitro could be translated in vivo, we 
chose to study BDL animals that are spontaneously mildly hyperammonemic. 
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Further exaggeration of hyperammonemia in these animals using a 
hyperammonemic diet resulted in an additional increased protein expression of HSC 
activation markers such as Myosin IIa and IIb, αSMA, PDFRβ and Collagen-1. These 
HSC markers were significantly reduced following treatment with OP, an ammonia 
lowering drug which has previously been shown to lower plasma ammonia 
concentrations.[28] These data provide direct in vivo evidence that 
hyperammonemia induces HSC activation and that lowering ammonia concentration 
reduces this activation. 
In order to test whether ammonia reduction is a target for the treatment of portal 
hypertension, we chose to study the BDL animal model, which is known to exhibit 
hyperammonemia, increased portal pressure and is clinically relevant.[28] In this 
model, the effect of ammonia reduction on eNOS activity in the brain was previously 
investigated using OP. The results showed reduction in brain water and improved 
brain eNOS activity through effects upon eNOS regulators.[50] The same model was 
used in this study to examine the effect of OP on portal pressure. Reduction in 
ammonia with OP was associated with a significant and marked reduction in portal 
pressure to values that were not significantly different to control animals without any 
significant change in the mean arterial pressure. This improvement in portal pressure 
was associated with a reduction in markers of oxidative and nitrosative stress such 
as iNOS and 5-nitrotyrosine, and induction in eNOS enzyme activity.  
In conclusion, the data presented in this paper provide the first indication that 
ammonia affects HSCs cell behaviour by changing ER dynamics and producing 
oxidative stress that result in HSC activation, and functional and morphological 
disturbances. This leads to the generation of many pro-inflammatory, contractile and 
pro-fibrogenic genes and proteins in vitro and in vivo. Importantly, by removal of 
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ammonia in vitro, or by lowering ammonia in vivo, HSC biology is restored. Indeed, 
reduction in ammonia concentration in a clinically relevant rat model of cirrhosis 
using OP (OCR-002), a drug in development for treatment of hyperammonemia and 
HE, resulted in a downregulation of HSCs activation markers, which coincided with a 
reduction in severity of many important pathophysiological determinants of portal 
hypertension. This suggests that ammonia is a possible target for therapy and 
justifies a clinical trial of ammonia lowering in portal hypertension.  
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FIGURE LEGENDS 
Fig. 1. Ammonia reduces in a dose dependent manner cell proliferation and 
metabolism in primary human Hepatic Stellate Cells in vitro. (A) Ammonia 
inhibits DNA synthesis (BrdU) and metabolic activity (MTS), (B) without inducing cell 
death. (C) Ammonia induced strong morphological changes in a dose-dependent 
manner i.e. from myofibroblast-like cells into spindle like fibroblasts as was observed 
by light microscopy and by Neutral Red cell viability test (20X, 40X). Bar graphs 
show means of three independent values ± SD. *P < .05, **P < .01 and ***P < .001 
vs. corresponding values of serum free medium (SFM). 
 
Fig. 2. Ammonia induces alterations in cytoplasmic stress, which coincides 
with changes in cellular metabolism/function, contraction and actin 
cytoskeleton architecture. 
(A) Transmission Electron Microscopy (TEM) shows that ammonia in a dose-
dependent manner caused dramatic morphological changes with appearance of 
cytoplasmic vacuoles (V=vacuoles; N=nucleus). (B) Recovery of cell proliferation 
after depletion of ammonia-rich culture medium. Bar graphs show means of three 
independent values ± SD. *P < .05 and ***P < .001 vs. SFM. (C, D) Collagen gel 
contraction assay shows that ammonia induces hHSC contraction. Bar graphs show 
means of 2 independent experiments (values ± SD. *P < .05 and **P < .01 vs. 
corresponding values of SFM. (E) Ammonia-induced HSC contraction coincides with 
changes in morphology. (F) Prolonged treatment (72h) with ammonia induces in a 
dose-dependent manner the re-organization of filamentous actin (TRITC-Phalloidin 
staining). 
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Fig. 3. Ammonia induces ER-stress. 
(A) Ammonia affects mRNA expression levels of ER stress markers ATF6 and XBP1 
in a dose and time-dependent manner. Bar graphs show means of 2 independent 
values ± SD. ***P < .001 vs corresponding values of SFM. (B) Pretreatment of hHSC 
with TUDCA, a chemical chaperone of ER stress, abrogates ammonia-induced ATF6 
and XBP1 mRNA expression. Bar graphs show means of 2 independent values ± 
SD. *P < .05 **P < .01 vs corresponding values of SFM. (C) Prolonged treatment of 
cells with ammonia for 72 hours induces ER-enlargement in hHSC. Changes in ER 
dynamics are observed by ER-Tracker™ Red.  
 
Fig. 4. Ammonia induces ROS production. 
(A) Prolonged treatment of hHSC with ammonia for 72 hours induces ROS 
production in hHSC. The formation of reactive oxygen species (ROS) was measured 
using Image-IT™ LIVE Green Reactive Oxygen Species Detection Kit. (B) Mean 
fluorescence intensity (MFI) of ROS signal was normalized according to the number 
of cells (Hoechst 33342), and expressed as percentage of control. Bar graphs show 
means of three independent values ± SD. ***P < .001 vs corresponding values of 
SFM. (C) Hyperammonemia increases mRNA expression level of ROS marker 
SOD2 at 3 and 24 hours. Bar graphs show means of 2 independent values ± SD. 
***P < .001 vs corresponding values of SFM. (D) NAC-induced ROS scavenger 
reduces ammonia-induced SOD2 mRNA expression at 24 hours. Bar graphs show 
means of 2 independent values ± SD. *P < .05 **P < .01 vs corresponding values of 
SFM.   
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Fig. 5. Ammonia modifies mRNA expression and protein level of several pro-
inflammatory and HSC activation markers. 
(A) Ammonia affects protein expression of α-SMA, vimentin, PDGF-Rβ, Myosin IIa 
and IIb, and p-38 MAPK. (B) Ammonia induces up-regulation of MMP2 mRNA 
whereas TIMP1 mRNA is down-regulated, and (C) Interleukin 1β and Interleukin IL6 
mRNA expression are upregulated. Bar graphs show means of three independent 
values ± SD. *P < .05, **P < .01 and ***P < .001 vs. corresponding values of SFM. 
 
Fig. 6. Hyperammonemia treatment further enhances BDL-induced HSC 
markers in vivo. 
(A) Plasma levels of ammonia are significant upregulated in BDL and AAs-fed BDL 
animals in comparison to sham operated rats (*P < .05 and **P < .01 vs Sham). OP 
treatment reduces significant ammonia in BDL-AAs-fed animals in comparison to 
BDL animals (**P < .01). (B) Hyperammonemia treatment in BDL-induced fibrosis 
showed an additional significant increase in Myosin IIb, Collagen type I and PDGF-
Rβ protein expression in comparison to BDL-induced fibrosis (**P < .01 and ***P < 
.001). In contrast, treatment with OP, abrogated the strong effect of AAs-fed BDL on 
all HSC-related activation markers (*P < .05, **P < .01 and ***P < .001). (C) CHOP 
protein expression was increased in BDL and BDL-AAs-fed animals with a minor but 
significant down regulation in BDL–AAs-OP-treated animals (*P < .05 vs BDL -AAs-
fed). BiP protein expression was significantly down regulated in all BDL treated 
animals in comparison to Sham-operated rats, whereas OP treatment significantly 
prevented BiP protein down regulation in comparison to BDL–AAs-fed animals (*P < 
.05 vs BDL -AAs-fed).  
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Fig. 7. Treatment with OP improves portal pressure through reduction in 
nitrosative stress. (A) Portal pressure show to be increased in BDL rats compared 
to sham (***P < .001). Administration of OP results in a significant lowering of portal 
pressure compared to BDL–saline treated rats (**P < .01). Mean arterial pressure 
(MAP) was significantly higher in sham rats compared with BDL animals (**P < .01) 
with no change observed between BDL and OP treated rats (NS). (B) iNOS protein 
expression in BDL rats significantly increases when compared to sham animals (***P 
< .001), whereas treatment with OP significantly reduces iNOS expression when 
compared to BDL animals (**P < .01). 3-NTyrosine expression was significantly up-
regulated in BDL treated animals compared to sham and this was reduced 
significantly following treatment with OP (**P< .01 vs. Sham, *P < .05 vs. BDL). (C) 
Protein expression of eNOS was significantly increased in BDL rats compared to 
sham animals (***P < .001) and remained unchanged after OP therapy. A significant 
reduced eNOS activity was observed in BDL rats compared to sham-operated 
animals (*P < .05) and this was restored to near normal levels after OP therapy (*P < 
.05 vs BDL). Caveolin-1 expression was upregulated in BDL livers compared to 
sham rats (***P < .001) and was downregulated upon with OP treatment (**P < .01 
vs. BDL). 
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